Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway

This study is looking at how to better support adults aged 65 and older who are receiving chemotherapy for cancer. It aims to understand their needs by measuring their resilience and then creating care plans tailored to each person. The study uses "Supportive Care" which includes a geriatric assessment (a check-up focused on older adults' health) and weekly reports from patients about their symptoms. We want to see how many people join the study, how many stay in it, and how many complete the weekly symptom assessments. We are looking for people aged 65 or older with cancer who are about to start chemotherapy and have been identified as pre-frail or frail.

Study design: This is a single-arm study, meaning everyone receives the same intervention, and plans to enroll 32 participants.
What's involved: You would have a baseline assessment, receive information about your frailty, be offered referrals for supportive care, and complete weekly symptom reporting (electronic survey + phone call) for 12 weeks.
Compensation: Not stated in the trial record.
Follow-up: Follow-up assessments will be completed at 12 weeks after initiation of standard of care chemotherapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway

Recruiting

NAAges 65+InterventionalSupportive care

Wake Forest University Health Sciences

~32 participants

Updated 2026-07-02 on ClinicalTrials.gov

What's tested:Supportive Care

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Recruitment rate

Measured over Enrollment

+2 more outcomes measured

Conditions

Cancer

Frail

Chemotherapy

Where it's being run

2 sites across 1 states

North Carolina2

Study leadership

Heidi Klepin, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

James Morgan

[email protected]

336-702-4491

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Ability to understand and willingness to sign an IRB-approved informed consent

Age ≥ 65 years at the time of enrollment.

Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic/immune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.

eFI pre-frail or frail status (available in EHR; defined as eFI \> 0.10) within 30 days before enrollment.

Ability to read and understand the English language

Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.

Exclusion

Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.

Chemotherapy planned at a facility outside the Atrium Health system.

Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).

What this trial measures

Recruitment rateEnrollment
The proportion of patients who are enrolled out of the total number of eligible patients approached for enrollment
Retention rateAt 12 weeks after initiation of standard of care chemotherapy
The proportion of enrolled patient participants who complete Visit 2 out of the total number of patient participants who were enrolled and initiate chemotherapy
Completion rate of Weekly Symptom AssessmentWeeks 1 to 12
The total number of weekly assessments completed out of the total number of weekly assessments among participants who enroll and initiate chemotherapy.

Trialytics